Review



glycochenodeoxycholic acid  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress glycochenodeoxycholic acid
    Glycochenodeoxycholic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 9 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/pm36037317-73-17-22
    Average 94 stars, based on 9 article reviews
    glycochenodeoxycholic acid - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    Sonication:

    Article Title: Engineered novel protease-stable multifunctional peptides attenuate metabolic dysfunction-associated steatotic liver disease via disrupting bile acid micelle and activating PPAR pathway.
    Article Snippet: .. The bile acid micellar solutions were prepared by sonication, containing the following components: 0.25 mM cholesterol (C8667–1G, Sigma-Aldrich), 0.5 mM oleic acid (O1008–1G, Sigma-Aldrich), 0.3 mM phosphorylcholine (HY-W040193, MedChemExpress), 0.25 mM monoolein (HY− 128754, MedChemExpress), and 3.3 mM taurocholic acid (TCA) (S100834, Aladdin), glycocholic acid (GCA) (HY-N1423, MedChemExpress), taurochenodeoxycholic acid (TCDCA) (HY-N2027, MedChemExpress) or glycochenodeoxycholic acid (GCDCA) (HYN2334, MedChemExpress) in PBS, each prepared separately. .. After incubation at 37◦C for 24 h, 5 mM peptide (GenScript) or CTY (C302192–100g, Aladdin) was added to the bile acid micellar solutions, incubated at 37◦C for 1 h, and centrifuged at 12000 × g for 15 min.

    other:

    Article Title: Targeting FDFT1 Reduces Cholesterol and Bile Acid Production and Delays Hepatocellular Carcinoma Progression Through the HNF4A/ALDOB/AKT1 Axis.
    Article Snippet: Capivasertib (HY-15431), YM-53601 (HY-100313A), MK-2206 (HY-10358), SC79 (HY18749), cholic acid (CA, HY-N0324), taurocholic acid (TCA, HY-B1788), glycocholic acid (GCA, HY-N1423), taurochenodeoxycholic acid (TCDCA, HY-N2027), glycochenodeoxycholic acid (GCDCA, HY-N2334), lithocholic acid (LCA, HY-B0172), taurolithocholic acid (TLCA, HY-113308), glycolithocholic acid (GLCA, HY-116374), deoxycholic acid (DCA, HY-N0593), taurodeoxycholic acid (TDCA, HY-B1899), glycodeoxycholic acid (GDCA, HY-125731), ursodeoxycholic acid (UDCA, HY-13771), tauroursodeoxycholic acid (TUDCA, HY-19696), glycoursodeoxycholic acid (GUDCA, HYN1424) and chenodeoxycholic acid (CDCA, HY-76847) were purchased from MedChem Express (USA).

    Virus:

    Article Title: Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma.
    Article Snippet: In brief Huang et al. reveal that high bile acid levels in the cholangiocarcinoma tumor microenvironment activate GPBAR1 on cancer-associated fibroblasts, inducing CXCL10 secretion.. This recruits neutrophils and maintains their immature phenotype, thereby potentiating immunosuppression.. Targeting GPBAR1 or CXCL10 enhances pembrolizumab response, offering a potential strategy to improve cholangiocarcinoma immunotherapy efficacy.

    Recombinant:

    Article Title: Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma.
    Article Snippet: In brief Huang et al. reveal that high bile acid levels in the cholangiocarcinoma tumor microenvironment activate GPBAR1 on cancer-associated fibroblasts, inducing CXCL10 secretion.. This recruits neutrophils and maintains their immature phenotype, thereby potentiating immunosuppression.. Targeting GPBAR1 or CXCL10 enhances pembrolizumab response, offering a potential strategy to improve cholangiocarcinoma immunotherapy efficacy.



    Similar Products

    glycochenodeoxycholic acid gcdca  (MedChemExpress)
    94
    MedChemExpress glycochenodeoxycholic acid gcdca
    Glycochenodeoxycholic Acid Gcdca, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/pm42442519-59-54-58
    Average 94 stars, based on 1 article reviews
    glycochenodeoxycholic acid gcdca - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    gcdca concentrations  (MedChemExpress)
    94
    MedChemExpress gcdca concentrations
    <t>GCDCA</t> activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).
    Gcdca Concentrations, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/pmc12597836-55-18-23
    Average 94 stars, based on 1 article reviews
    gcdca concentrations - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    glycochenodeoxycholic acid  (MedChemExpress)
    94
    MedChemExpress glycochenodeoxycholic acid
    <t>GCDCA</t> activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).
    Glycochenodeoxycholic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/custom%40hy-n2334%4041220403
    Average 94 stars, based on 1 article reviews
    glycochenodeoxycholic acid - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    gcdca mce  (MedChemExpress)
    94
    MedChemExpress gcdca mce
    <t>GCDCA</t> activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).
    Gcdca Mce, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/pm40578361-597-142-143
    Average 94 stars, based on 1 article reviews
    gcdca mce - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cba glycochenodeoxycholic acid  (MedChemExpress)
    94
    MedChemExpress cba glycochenodeoxycholic acid
    <t>GCDCA</t> activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).
    Cba Glycochenodeoxycholic Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/hy-n2334/Glycochenodeoxycholic+acid/pmc09834486-47-103-106
    Average 94 stars, based on 1 article reviews
    cba glycochenodeoxycholic acid - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    GCDCA activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).

    Journal: Journal of Inflammation Research

    Article Title: Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells

    doi: 10.2147/JIR.S532042

    Figure Lengend Snippet: GCDCA activates the NLRP3 inflammasome in hepatocytes. ( A ) Dose-dependent effects of GCDCA (25–400 μM, 24 h) on protein levels effects of NLRP3, ASC, pro-caspase-1, caspase-1 P20, pro-IL-1β and GAPDH. ( B ) Time-dependent effects of these proteins in L02 cells treated with 200 μM GCDCA. ( C and D ) Synergistic priming by LPS (1 μg/mL, 4 h pre-treatment): GCDCA (50–400 μM, 24 h) ( C ) or time-dependent (12–72 h) ( D ) enhancement of NLRP3, pro-caspase-1, and pro-IL-1β expression in LPS-primed cells. ( E ) Comparative analysis of NLRP3 inflammasome activationin L02 cells treated with GCDCA (200 μM, 24 h) with/without LPS co-stimulation. ( F ) Essential role of NLRP3 in GCDCA-induced pyroptosis. L02 cells were pretreated with/without LPS (1 μg/mL, 4 h) and MCC950 (10 μM, 2 h) prior to GCDCA (200 μM, 24 h) exposure. Whole cell lysates were examined by Western Blot analysis. Molecular weight markers (kDa) are indicated. n ≥ 3 for each group. (LG200: LPS+200 μM GCDCA; G200: GCDCA 200 μM).

    Article Snippet: L02 and LX2 cells were synchronized in serum-free medium for 12 h. L02 cells were exposed to graded GCDCA concentrations (25–400 μM, HY-N2334, MCE) for 24 h or 200 μM GCDCA for 6–72 h to establish dose/time-response profiles.

    Techniques: Expressing, Western Blot, Molecular Weight

    GCDCA induces GSDMD-mediated pyroptosis in hepatocytes. ( A and B ) Time- and dose-dependent LDH release in LPS-primed L02 cells treated with GCDCA: ( A ) Dose-response (50–400 μM GCDCA, 24 h); ( B ) Time-course (200 μM GCDCA, 12–72 h). ( C ) Dose-dependent GSDMD proteolysis in LPS-primed cells treated with GCDCA (50–400 μM, 24 h); ( D ) Time-dependent GSDMD proteolysis (200 μM GCDCA, 12–72 h). GAPDH serves as loading control. ( E ) Validation of GSDMD knockdown efficiency in L02 cells. ( F ) LDH release in lentiviruses-transfected L02 cells treated with GCDCA (200 μM, 24 h). ( G ) Representative flow plots showing Annexin V/PI staining in lentiviruses-transfected L02 cells. ( H ) Flow cytometry quantification of pyroptotic cells (Annexin V⁺/PI⁺). n ≥ 3 for each group. a P < 0.005, b P < 0.05, c P < 0.0001.

    Journal: Journal of Inflammation Research

    Article Title: Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells

    doi: 10.2147/JIR.S532042

    Figure Lengend Snippet: GCDCA induces GSDMD-mediated pyroptosis in hepatocytes. ( A and B ) Time- and dose-dependent LDH release in LPS-primed L02 cells treated with GCDCA: ( A ) Dose-response (50–400 μM GCDCA, 24 h); ( B ) Time-course (200 μM GCDCA, 12–72 h). ( C ) Dose-dependent GSDMD proteolysis in LPS-primed cells treated with GCDCA (50–400 μM, 24 h); ( D ) Time-dependent GSDMD proteolysis (200 μM GCDCA, 12–72 h). GAPDH serves as loading control. ( E ) Validation of GSDMD knockdown efficiency in L02 cells. ( F ) LDH release in lentiviruses-transfected L02 cells treated with GCDCA (200 μM, 24 h). ( G ) Representative flow plots showing Annexin V/PI staining in lentiviruses-transfected L02 cells. ( H ) Flow cytometry quantification of pyroptotic cells (Annexin V⁺/PI⁺). n ≥ 3 for each group. a P < 0.005, b P < 0.05, c P < 0.0001.

    Article Snippet: L02 and LX2 cells were synchronized in serum-free medium for 12 h. L02 cells were exposed to graded GCDCA concentrations (25–400 μM, HY-N2334, MCE) for 24 h or 200 μM GCDCA for 6–72 h to establish dose/time-response profiles.

    Techniques: Control, Biomarker Discovery, Knockdown, Transfection, Staining, Flow Cytometry

    GCDCA triggers caspase-1-dependent pyroptosis in hepatocytes. ( A and B ) Caspase-1/4 activity in LPS-primed L02 cells treated with GCDCA. ( C and D ) Flow cytometry quantification of pyroptotic cells (Annexin V⁺/PI⁺) in L02 cells with caspase-1 inhibitor Ac-YVAD-cmk (AC, 50 μM) followed by LPS + GCDCA (200 μM, 24 h). ( E ) LDH release in L02 cells with AC pretreatment. (F)Western blot analysis of pyroptosis-related proteins in L02 cells with AC pretreatment. n ≥ 3 for each group. a P < 0.005, b P < 0.0001.

    Journal: Journal of Inflammation Research

    Article Title: Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells

    doi: 10.2147/JIR.S532042

    Figure Lengend Snippet: GCDCA triggers caspase-1-dependent pyroptosis in hepatocytes. ( A and B ) Caspase-1/4 activity in LPS-primed L02 cells treated with GCDCA. ( C and D ) Flow cytometry quantification of pyroptotic cells (Annexin V⁺/PI⁺) in L02 cells with caspase-1 inhibitor Ac-YVAD-cmk (AC, 50 μM) followed by LPS + GCDCA (200 μM, 24 h). ( E ) LDH release in L02 cells with AC pretreatment. (F)Western blot analysis of pyroptosis-related proteins in L02 cells with AC pretreatment. n ≥ 3 for each group. a P < 0.005, b P < 0.0001.

    Article Snippet: L02 and LX2 cells were synchronized in serum-free medium for 12 h. L02 cells were exposed to graded GCDCA concentrations (25–400 μM, HY-N2334, MCE) for 24 h or 200 μM GCDCA for 6–72 h to establish dose/time-response profiles.

    Techniques: Activity Assay, Flow Cytometry, Western Blot

    GCDCA drives IL-1β secretion through GSDMD-dependent activation. ( A ) Dose-dependent IL-1β secretion in LPS-primed L02 cells treated with GCDCA (50–400 μM, 24 h). ( B )Time-dependent IL-1β secretion (200 μM GCDCA, 12–72 h). ( C ) Western blot analysis of GSDMD-NT and GSDMD in L02 cells and mature IL-1β in cell supernatant. ( D ) ELISA quantification of extracellular IL-1β. n ≥ 3 for each group. a P < 0.01.

    Journal: Journal of Inflammation Research

    Article Title: Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells

    doi: 10.2147/JIR.S532042

    Figure Lengend Snippet: GCDCA drives IL-1β secretion through GSDMD-dependent activation. ( A ) Dose-dependent IL-1β secretion in LPS-primed L02 cells treated with GCDCA (50–400 μM, 24 h). ( B )Time-dependent IL-1β secretion (200 μM GCDCA, 12–72 h). ( C ) Western blot analysis of GSDMD-NT and GSDMD in L02 cells and mature IL-1β in cell supernatant. ( D ) ELISA quantification of extracellular IL-1β. n ≥ 3 for each group. a P < 0.01.

    Article Snippet: L02 and LX2 cells were synchronized in serum-free medium for 12 h. L02 cells were exposed to graded GCDCA concentrations (25–400 μM, HY-N2334, MCE) for 24 h or 200 μM GCDCA for 6–72 h to establish dose/time-response profiles.

    Techniques: Activation Assay, Western Blot, Enzyme-linked Immunosorbent Assay

    GCDCA-mediated hepatocyte IL-1β secretion activates HSCs. ( A ) Western blot analysis ofα-SMA and Collagen-I in LX2 cells treated with conditioned medium (CM) from GCDCA/LPS-stimulated L02 hepatocytes. ( B ) The protein levels of α-SMA and Collagen-I in LX2 cells with treatment of IL-1 receptor antagonist (IL-1RA, 200 ng/mL) upon CM exposure. ( C and D ) Representative images and quantification of LX2 migration upon CM exposure detected by wound healing assay. ( E ) CCK-8 assay of LX2 proliferation by CM treatment. n ≥ 3 for each group. a P < 0.05.

    Journal: Journal of Inflammation Research

    Article Title: Glycochenodeoxycholic acid induces the release of IL-1beta from L02 cells via the NLRP3/caspase-1/GSDMD pathway to activate LX2 cells

    doi: 10.2147/JIR.S532042

    Figure Lengend Snippet: GCDCA-mediated hepatocyte IL-1β secretion activates HSCs. ( A ) Western blot analysis ofα-SMA and Collagen-I in LX2 cells treated with conditioned medium (CM) from GCDCA/LPS-stimulated L02 hepatocytes. ( B ) The protein levels of α-SMA and Collagen-I in LX2 cells with treatment of IL-1 receptor antagonist (IL-1RA, 200 ng/mL) upon CM exposure. ( C and D ) Representative images and quantification of LX2 migration upon CM exposure detected by wound healing assay. ( E ) CCK-8 assay of LX2 proliferation by CM treatment. n ≥ 3 for each group. a P < 0.05.

    Article Snippet: L02 and LX2 cells were synchronized in serum-free medium for 12 h. L02 cells were exposed to graded GCDCA concentrations (25–400 μM, HY-N2334, MCE) for 24 h or 200 μM GCDCA for 6–72 h to establish dose/time-response profiles.

    Techniques: Western Blot, Migration, Wound Healing Assay, CCK-8 Assay